Healthcare News

REYKJAVIK, Iceland, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...

REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

REYKJAVÍK (31. ágúst 2026) – Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hefði tekið til afgreiðslu umsókn um markaðsleyfi í Bandaríkjunum fyrir...

First clinical trial in Atrial Fibrillation using implanted and wearable cardiac monitors to determine the correct dose of a novel drug to suppress AF.

10XB-101 is a Novel Potential Best-in-Class Injectable Drug Being Developed for Focal Fat Reduction and Body Contouring  Second Major Regional Licensing and Strategic Investment Agreement in 2026;...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from...

VB Health is leading the supplement industry in transparency and scientific testing by publicly releasing their COA data.

- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing...

Durham, N.C., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Phase 2 GenePHIT trial successfully randomized and completed enrollment of one of the largest gene therapy trials conducted in heart failure to date,...

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112) In the same patient population,...